BMEA - Rasio utang marang kapitalisasi buku Biomea Fusion Inc

Biomea Fusion, Inc. (BMEA) serves as a leading developer of covalent compounds to combat metabolic disorders and diabetes, backed by significant scientific weight. This price trend reflects the asset's dynamics, with its current value standing at 0.07. The company's projects focus on creating targeted therapies for oncology and endocrine pathologies. Under Thomas Butler's leadership, the firm is currently navigating critical trial stages, which is driving moderate volatility in the share price.

BMEA (Biomea Fusion Corp) riwayat Utang marang nilai buku saka 04.07.2022 nganti 28.10.2026

Biomea Fusion Inc (BMEA) - rincian metrik lan laporan keuangan

- rega lan prakiraan konsensus rega:

Rega saham Biomea Fusion, Inc.|BMEA - Prakiraan konsensus analis

- data kapitalisasi pasar:

Nilai pasar Biomea Fusion Corp|BMEA - Nilai Dipunlarasaken Utang lan Kas

- data kapitalisasi buku:

Aset Bersih saben Siji Saham Biomea Fusion|BMEA - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku biomeafusion.com|BMEA - Total Aset Perusahaan

- data utang lan likuiditas:

Rasio Total Utang marang Ekuitas Biomea Fusion, Inc.|BMEA - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Biomea|BMEA - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Biomea Fusion Corp

Analisis fundamental perusahaan:Biomea Fusion, Inc. - BMEA

This indicator measures the proportion of borrowed funds relative to equity, allowing for an assessment of financial leverage and the extent of the business's dependence on creditors. The stability of the healthcare sector and the insulation of Biomea Fusion, Inc. (BMEA) research from geopolitics make the company's debt relative to its book capitalization a reliable marker of resilience, confirming low default risks during the development of innovations.

Pesaing Biomea Fusion, Inc. (BMEA)